Healthcare - Biotechnology - NASDAQ - US
$ 2.5
-6.72 %
$ 4.94 M
Market Cap
-0.22
P/E
CASH FLOW STATEMENT
-10.9 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
5.91 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
180 Life Sciences Corp.
| Net Income | -19.9 M |
| Depreciation & Amortization | 106 K |
| Capital Expenditures | 3 |
| Stock-Based Compensation | 2.28 M |
| Change in Working Capital | -14.1 K |
| Others | 8.69 M |
| Free Cash Flow | -10.9 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (19.9) | (38.7) | (20.3) | (10.9) | (25.4) | (14.5) | 0.1 |
| Depreciation & Amortization | 0.1 | 0.1 | 0.1 | 0.1 | 72.2 K | 23.1 K | 0 |
| Deferred Income Tax | (2.3) | (0.9) | 24.8 K | 20.4 K | 9.5 K | 0 | 0 |
| Stock Based Compensation | 2.3 | 3.0 | 5.0 | 1.1 | 13.3 | 4.6 | 0 |
| Other Operating Activities | 9.0 | 22.1 | 6.8 | 3.5 | 5.7 | 6.1 | (0.6) |
| Change in Working Capital | 14.1 K | 2.7 | (8.8) | 2.3 | 3.0 | (0.1) | 53.6 K |
| Cash From Operations | (10.9) | (12.1) | (19.4) | (3.9) | (3.3) | (3.9) | (0.5) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 3 | 0 | 0 | 0 | (0.1) | 30.8 K | 0 |
| Other Items | 3 | 0 | 0 | 14.5 | (0.6) | 60 K | (115.9) |
| Cash From Investing Activities | 0 | 0 | 0 | 14.5 | (0.7) | 90.8 K | (115.9) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | (1.0) | 0 | (9.0) | 0 | 0 | 0 |
| Total Debt Repaid | (0.3) | (0.5) | 0.8 | 0.3 | 2.7 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.2 | 11.4 | (2.1) | (0.1) | 1.3 | 4.8 | 116.8 |
| Cash From Financing Activities | 5.9 | 10.9 | 25.4 | (8.7) | 3.9 | 4.8 | 116.8 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (5.0) | (1.3) | 6.1 | 2.0 | (0.5) | (0.2) | 0.4 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (10.9) | (12.1) | (19.4) | (3.9) | (3.5) | (3.9) | (0.5) |